| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
ICON Public Limited Company (NASDAQ: ICLR)
ICLR Technical Analysis
4
| As on 9th Jun 2023 ICLR SHARE Price closed @ 221.93 and we RECOMMEND Sell for LONG-TERM with Stoploss of 228.18 & Strong Sell for SHORT-TERM with Stoploss of 263.56 we also expect STOCK to react on Following IMPORTANT LEVELS. |
ICLRSHARE Price
| Open | 225.81 | Change | Price | % |
| High | 225.81 | 1 Day | -3.13 | -1.39 |
| Low | 221.09 | 1 Week | 8.90 | 4.18 |
| Close | 221.93 | 1 Month | 31.22 | 16.37 |
| Volume | 457000 | 1 Year | -64.77 | -22.59 |
| 52 Week High 309.70 | 52 Week Low 173.90 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| ICLR Daily Charts |
ICLR Intraday Charts |
Whats New @ Bazaartrend |
ICLR Free Analysis |
|
|
ICLR Important Levels Intraday
| RESISTANCE | 231.03 |
| RESISTANCE | 228.11 |
| RESISTANCE | 226.31 |
| RESISTANCE | 224.50 |
| SUPPORT | 219.36 |
| SUPPORT | 217.55 |
| SUPPORT | 215.75 |
| SUPPORT | 212.83 |
ICLR Forecast April 2024
| 4th UP Forecast | 354.74 |
| 3rd UP Forecast | 312.15 |
| 2nd UP Forecast | 285.82 |
| 1st UP Forecast | 259.49 |
| 1st DOWN Forecast | 184.37 |
| 2nd DOWN Forecast | 158.04 |
| 3rd DOWN Forecast | 131.71 |
| 4th DOWN Forecast | 89.12 |
ICLR Weekly Forecast
| 4th UP Forecast | 289.12 |
| 3rd UP Forecast | 267.57 |
| 2nd UP Forecast | 254.25 |
| 1st UP Forecast | 240.93 |
| 1st DOWN Forecast | 202.93 |
| 2nd DOWN Forecast | 189.61 |
| 3rd DOWN Forecast | 176.29 |
| 4th DOWN Forecast | 154.74 |
ICLR Forecast2024
| 4th UP Forecast | 494.74 |
| 3rd UP Forecast | 407.25 |
| 2nd UP Forecast | 353.17 |
| 1st UP Forecast | 299.09 |
| 1st DOWN Forecast | 144.77 |
| 2nd DOWN Forecast | 90.69 |
| 3rd DOWN Forecast | 36.61 |
| 4th DOWN Forecast | -50.88 |
ICON Public Limited Company ( NASDAQ USA Symbol : ICLR )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
ICLR Business Profile
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It offers clinical development services, including product development planning, strategic consulting, study protocol preparation, clinical pharmacology, pharmacokinetic and pharmacodynamic analysis, site feasibility, patient recruitment and retention, digital patient and site, project management, clinical operations/monitoring, patient centric monitoring, data management, and adaptive and virtual trial services. The company's clinical development services also comprise medical imaging, biostatistics, medical affairs, pharmacovigilance, strategic regulatory, electronic endpoint adjudication, medical writing and publishing, interactive response technologies, functional solutions, strategic resourcing central laboratory, bioanalytical laboratory, biomarket development, strategy and analytics, late phase research, patient centered science, and medical device and diagnostics research services, as well as access, commercialization, and communication services, and research trials for us government agencies. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON has an agreement with Evergreen Therapeutics, Inc. to conduct Phase II clinical trial for COVID-19 drug candidate. The company was incorporated in 1990 and is headquartered in Dublin, Ireland. Address: South County Business Park, Dublin, Ireland, 18
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service